Genetisch basierte Therapien bei spinaler Muskelatrophie View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2022-05-06

AUTHORS

T. Hagenacker, U. Schara-Schmidt, C. Kleinschnitz

ABSTRACT

BackgroundThe 5q-associated spinal muscular atrophy (SMA) affects ~ 80–120 newborns annually. The disease is characterized by progressive paresis involving the bulbar and respiratory musculatures. The phenotypes are very heterogeneous ranging from severe courses with early death in the first years of life to loss of gait in older age.ObjectiveThere are now an increasing number of causally targeted therapies available that can either directly interfere with the transcription of the gene causing the disease or replace the homozygous loss of the SMN1 gene. This work aims to elucidate the current state of therapy in different groups of patients with SMA.Material and methodsPresentation of clinical trials and basic studies with a focus on patients with disease onset in adulthood.ResultsThe clinical studies all show improvement or stabilization of motor function; however, in individual cases, the burden of the therapy for severely immobilized patients must be considered in addition to the efficacy in the treatment decision. Even if the drugs show a good safety profile, observations on the long-term efficacy and safety of the new substance classes are still lacking.ConclusionThe study landscape shows a good efficacy of the currently approved therapies across all degrees of severity and age groups. Due to the lack of comparative studies, the decision on the appropriate therapy should therefore be made according to an individual risk-benefit assessment. More... »

PAGES

549-556

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00115-022-01295-1

DOI

http://dx.doi.org/10.1007/s00115-022-01295-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1147664516

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35522309


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gait", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infant, Newborn", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Muscular Atrophy, Spinal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligonucleotides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenotype", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Universit\u00e4tsmedizin Essen, Klinik f\u00fcr Neurologie und Center for Translational Neuro- and Behavioral Science, Hufelandstr.\u00a055, 45147, Essen, Deutschland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Universit\u00e4tsmedizin Essen, Klinik f\u00fcr Neurologie und Center for Translational Neuro- and Behavioral Science, Hufelandstr.\u00a055, 45147, Essen, Deutschland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hagenacker", 
        "givenName": "T.", 
        "id": "sg:person.01320640500.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320640500.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e4tsmedizin Essen, Klinik f\u00fcr Kinderheilkunde 1, Abteilung f\u00fcr Neurop\u00e4diatrie, Essen, Deutschland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Universit\u00e4tsmedizin Essen, Klinik f\u00fcr Kinderheilkunde 1, Abteilung f\u00fcr Neurop\u00e4diatrie, Essen, Deutschland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schara-Schmidt", 
        "givenName": "U.", 
        "id": "sg:person.01133657416.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133657416.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e4tsmedizin Essen, Klinik f\u00fcr Neurologie und Center for Translational Neuro- and Behavioral Science, Hufelandstr.\u00a055, 45147, Essen, Deutschland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Universit\u00e4tsmedizin Essen, Klinik f\u00fcr Neurologie und Center for Translational Neuro- and Behavioral Science, Hufelandstr.\u00a055, 45147, Essen, Deutschland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kleinschnitz", 
        "givenName": "C.", 
        "id": "sg:person.01004271214.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004271214.05"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00115-020-00919-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1127514887", 
          "https://doi.org/10.1007/s00115-020-00919-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng0797-265", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051068967", 
          "https://doi.org/10.1038/ng0797-265"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00234-019-02189-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1112731519", 
          "https://doi.org/10.1007/s00234-019-02189-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13023-021-01903-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1138847071", 
          "https://doi.org/10.1186/s13023-021-01903-4"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-05-06", 
    "datePublishedReg": "2022-05-06", 
    "description": "BackgroundThe 5q-associated spinal muscular atrophy (SMA) affects ~\u00a080\u2013120 newborns annually. The disease is characterized by progressive paresis involving the bulbar and respiratory musculatures. The phenotypes are very heterogeneous ranging from severe courses with early death in the first years of life to loss of gait in older age.ObjectiveThere are now an increasing number of causally targeted therapies available that can either directly interfere with the transcription of the gene causing the disease or replace the homozygous loss of the SMN1 gene. This work aims to elucidate the current state of therapy in different groups of patients with SMA.Material and methodsPresentation of clinical trials and basic studies with a\u00a0focus on patients with disease onset in adulthood.ResultsThe clinical studies all show improvement or stabilization of motor function; however, in individual cases, the burden of the therapy for severely immobilized patients must be considered in addition to the efficacy in the treatment decision. Even if the drugs show a\u00a0good safety profile, observations on the long-term efficacy and safety of the new substance classes are still lacking.ConclusionThe study landscape shows a good efficacy of the currently approved therapies across all degrees of severity and age groups. Due to the lack of comparative studies, the decision on the appropriate therapy should therefore be made according to an individual risk-benefit assessment.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00115-022-01295-1", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1018193", 
        "issn": [
          "0028-2804", 
          "1433-0407"
        ], 
        "name": "Der Nervenarzt", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "93"
      }
    ], 
    "keywords": [
      "spinal muscular atrophy", 
      "individual risk-benefit assessment", 
      "loss of gait", 
      "good safety profile", 
      "long-term efficacy", 
      "risk-benefit assessment", 
      "degree of severity", 
      "progressive paresis", 
      "severe course", 
      "appropriate therapy", 
      "safety profile", 
      "respiratory musculature", 
      "disease onset", 
      "clinical trials", 
      "motor function", 
      "clinical studies", 
      "treatment decisions", 
      "early death", 
      "new substance class", 
      "better efficacy", 
      "muscular atrophy", 
      "therapy", 
      "age groups", 
      "older age", 
      "patients", 
      "SMN1 gene", 
      "homozygous loss", 
      "efficacy", 
      "disease", 
      "first year", 
      "individual cases", 
      "paresis", 
      "atrophy", 
      "newborns", 
      "group", 
      "ObjectiveThere", 
      "different groups", 
      "trials", 
      "substance classes", 
      "severity", 
      "study", 
      "drugs", 
      "death", 
      "age", 
      "musculature", 
      "adulthood", 
      "gait", 
      "burden", 
      "onset", 
      "genes", 
      "MethodsPresentation", 
      "basic studies", 
      "phenotype", 
      "safety", 
      "loss", 
      "comparative study", 
      "years", 
      "course", 
      "assessment", 
      "cases", 
      "life", 
      "lack", 
      "improvement", 
      "transcription", 
      "profile", 
      "function", 
      "current state", 
      "addition", 
      "decisions", 
      "number", 
      "degree", 
      "focus", 
      "stabilization", 
      "observations", 
      "materials", 
      "state", 
      "class", 
      "work", 
      "landscape", 
      "study landscape"
    ], 
    "name": "Genetisch basierte Therapien bei spinaler Muskelatrophie", 
    "pagination": "549-556", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147664516"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00115-022-01295-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35522309"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00115-022-01295-1", 
      "https://app.dimensions.ai/details/publication/pub.1147664516"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:11", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_934.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00115-022-01295-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00115-022-01295-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00115-022-01295-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00115-022-01295-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00115-022-01295-1'


 

This table displays all metadata directly associated to this object as RDF triples.

205 TRIPLES      21 PREDICATES      117 URIs      105 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00115-022-01295-1 schema:about N0018858626494a3285ff78264118adda
2 N69e9f7ea115f4907a66916df7973f76f
3 N6e158624588c46b28fb861c21e24f2d0
4 Nb0155d769e99461fb4d39f302649b0f8
5 Nb40607d1debb4bdea3bccf2814b92633
6 Ndfa25e71d03d46b49c6ffc300f57625f
7 Ne7a14ec807974654a75498df76e52a74
8 Neeacd45441184447b1ac259b2523b476
9 anzsrc-for:11
10 anzsrc-for:1103
11 schema:author N8a3fc07924324bb18ed31267c5c2b3db
12 schema:citation sg:pub.10.1007/s00115-020-00919-8
13 sg:pub.10.1007/s00234-019-02189-x
14 sg:pub.10.1038/ng0797-265
15 sg:pub.10.1186/s13023-021-01903-4
16 schema:datePublished 2022-05-06
17 schema:datePublishedReg 2022-05-06
18 schema:description BackgroundThe 5q-associated spinal muscular atrophy (SMA) affects ~ 80–120 newborns annually. The disease is characterized by progressive paresis involving the bulbar and respiratory musculatures. The phenotypes are very heterogeneous ranging from severe courses with early death in the first years of life to loss of gait in older age.ObjectiveThere are now an increasing number of causally targeted therapies available that can either directly interfere with the transcription of the gene causing the disease or replace the homozygous loss of the SMN1 gene. This work aims to elucidate the current state of therapy in different groups of patients with SMA.Material and methodsPresentation of clinical trials and basic studies with a focus on patients with disease onset in adulthood.ResultsThe clinical studies all show improvement or stabilization of motor function; however, in individual cases, the burden of the therapy for severely immobilized patients must be considered in addition to the efficacy in the treatment decision. Even if the drugs show a good safety profile, observations on the long-term efficacy and safety of the new substance classes are still lacking.ConclusionThe study landscape shows a good efficacy of the currently approved therapies across all degrees of severity and age groups. Due to the lack of comparative studies, the decision on the appropriate therapy should therefore be made according to an individual risk-benefit assessment.
19 schema:genre article
20 schema:isAccessibleForFree false
21 schema:isPartOf N87d448382a4945448b8b5a91cfdcc072
22 Nfbe7e26dab9e4e1884114d721f868879
23 sg:journal.1018193
24 schema:keywords MethodsPresentation
25 ObjectiveThere
26 SMN1 gene
27 addition
28 adulthood
29 age
30 age groups
31 appropriate therapy
32 assessment
33 atrophy
34 basic studies
35 better efficacy
36 burden
37 cases
38 class
39 clinical studies
40 clinical trials
41 comparative study
42 course
43 current state
44 death
45 decisions
46 degree
47 degree of severity
48 different groups
49 disease
50 disease onset
51 drugs
52 early death
53 efficacy
54 first year
55 focus
56 function
57 gait
58 genes
59 good safety profile
60 group
61 homozygous loss
62 improvement
63 individual cases
64 individual risk-benefit assessment
65 lack
66 landscape
67 life
68 long-term efficacy
69 loss
70 loss of gait
71 materials
72 motor function
73 muscular atrophy
74 musculature
75 new substance class
76 newborns
77 number
78 observations
79 older age
80 onset
81 paresis
82 patients
83 phenotype
84 profile
85 progressive paresis
86 respiratory musculature
87 risk-benefit assessment
88 safety
89 safety profile
90 severe course
91 severity
92 spinal muscular atrophy
93 stabilization
94 state
95 study
96 study landscape
97 substance classes
98 therapy
99 transcription
100 treatment decisions
101 trials
102 work
103 years
104 schema:name Genetisch basierte Therapien bei spinaler Muskelatrophie
105 schema:pagination 549-556
106 schema:productId N042f70f959d640129336fba9058272fe
107 N52ecb9ca7981409e97b8705277b6af26
108 N7f82b2ac9f044c969a66af70abde4157
109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147664516
110 https://doi.org/10.1007/s00115-022-01295-1
111 schema:sdDatePublished 2022-08-04T17:11
112 schema:sdLicense https://scigraph.springernature.com/explorer/license/
113 schema:sdPublisher Nb97565bbe86146caaa626e9fc75665ef
114 schema:url https://doi.org/10.1007/s00115-022-01295-1
115 sgo:license sg:explorer/license/
116 sgo:sdDataset articles
117 rdf:type schema:ScholarlyArticle
118 N0018858626494a3285ff78264118adda schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Muscular Atrophy, Spinal
120 rdf:type schema:DefinedTerm
121 N042f70f959d640129336fba9058272fe schema:name dimensions_id
122 schema:value pub.1147664516
123 rdf:type schema:PropertyValue
124 N419e38d5d5414e4c86062fe20b1d366f rdf:first sg:person.01133657416.38
125 rdf:rest Nc8334bcad37f48f2be0e54167351b106
126 N52ecb9ca7981409e97b8705277b6af26 schema:name doi
127 schema:value 10.1007/s00115-022-01295-1
128 rdf:type schema:PropertyValue
129 N69e9f7ea115f4907a66916df7973f76f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Humans
131 rdf:type schema:DefinedTerm
132 N6e158624588c46b28fb861c21e24f2d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Risk Assessment
134 rdf:type schema:DefinedTerm
135 N7f82b2ac9f044c969a66af70abde4157 schema:name pubmed_id
136 schema:value 35522309
137 rdf:type schema:PropertyValue
138 N87d448382a4945448b8b5a91cfdcc072 schema:volumeNumber 93
139 rdf:type schema:PublicationVolume
140 N8a3fc07924324bb18ed31267c5c2b3db rdf:first sg:person.01320640500.40
141 rdf:rest N419e38d5d5414e4c86062fe20b1d366f
142 Nb0155d769e99461fb4d39f302649b0f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Adult
144 rdf:type schema:DefinedTerm
145 Nb40607d1debb4bdea3bccf2814b92633 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Infant, Newborn
147 rdf:type schema:DefinedTerm
148 Nb97565bbe86146caaa626e9fc75665ef schema:name Springer Nature - SN SciGraph project
149 rdf:type schema:Organization
150 Nc8334bcad37f48f2be0e54167351b106 rdf:first sg:person.01004271214.05
151 rdf:rest rdf:nil
152 Ndfa25e71d03d46b49c6ffc300f57625f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Gait
154 rdf:type schema:DefinedTerm
155 Ne7a14ec807974654a75498df76e52a74 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Phenotype
157 rdf:type schema:DefinedTerm
158 Neeacd45441184447b1ac259b2523b476 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Oligonucleotides
160 rdf:type schema:DefinedTerm
161 Nfbe7e26dab9e4e1884114d721f868879 schema:issueNumber 6
162 rdf:type schema:PublicationIssue
163 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
164 schema:name Medical and Health Sciences
165 rdf:type schema:DefinedTerm
166 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
167 schema:name Clinical Sciences
168 rdf:type schema:DefinedTerm
169 sg:journal.1018193 schema:issn 0028-2804
170 1433-0407
171 schema:name Der Nervenarzt
172 schema:publisher Springer Nature
173 rdf:type schema:Periodical
174 sg:person.01004271214.05 schema:affiliation grid-institutes:None
175 schema:familyName Kleinschnitz
176 schema:givenName C.
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004271214.05
178 rdf:type schema:Person
179 sg:person.01133657416.38 schema:affiliation grid-institutes:None
180 schema:familyName Schara-Schmidt
181 schema:givenName U.
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133657416.38
183 rdf:type schema:Person
184 sg:person.01320640500.40 schema:affiliation grid-institutes:None
185 schema:familyName Hagenacker
186 schema:givenName T.
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320640500.40
188 rdf:type schema:Person
189 sg:pub.10.1007/s00115-020-00919-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1127514887
190 https://doi.org/10.1007/s00115-020-00919-8
191 rdf:type schema:CreativeWork
192 sg:pub.10.1007/s00234-019-02189-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1112731519
193 https://doi.org/10.1007/s00234-019-02189-x
194 rdf:type schema:CreativeWork
195 sg:pub.10.1038/ng0797-265 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051068967
196 https://doi.org/10.1038/ng0797-265
197 rdf:type schema:CreativeWork
198 sg:pub.10.1186/s13023-021-01903-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1138847071
199 https://doi.org/10.1186/s13023-021-01903-4
200 rdf:type schema:CreativeWork
201 grid-institutes:None schema:alternateName Universitätsmedizin Essen, Klinik für Kinderheilkunde 1, Abteilung für Neuropädiatrie, Essen, Deutschland
202 Universitätsmedizin Essen, Klinik für Neurologie und Center for Translational Neuro- and Behavioral Science, Hufelandstr. 55, 45147, Essen, Deutschland
203 schema:name Universitätsmedizin Essen, Klinik für Kinderheilkunde 1, Abteilung für Neuropädiatrie, Essen, Deutschland
204 Universitätsmedizin Essen, Klinik für Neurologie und Center for Translational Neuro- and Behavioral Science, Hufelandstr. 55, 45147, Essen, Deutschland
205 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...